By Frank Prenesti
Date: Wednesday 27 Dec 2023
LONDON (ShareCast) - (Sharecast News) - AstraZeneca on Wednesday said it was buying Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, for $1.2bn.
Under the terms of the deal, AstraZeneca will acquire all of Gracell's shares at $2 per share in cash, plus a non-tradable contingent value right of $0.30 per ordinary share payable upon achievement of a specified regulatory milestone.
The upfront cash portion represents a 62% premium to Gracell's closing market price on December 22, 2023.
Reporting by Frank Prenesti for Sharecast.com
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 12,090.00p |
Change Today | -82.00p |
% Change | -0.67 % |
52 Week High | 12,370.00p |
52 Week Low | 9,501.00p |
Volume | 167,869 |
Shares Issued | 1,550.24m |
Market Cap | £187,423m |
RiskGrade | 123 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 8 |
Buy | 15 |
Neutral | 5 |
Sell | 0 |
Strong Sell | 1 |
Total | 29 |
Latest | Previous | |
---|---|---|
2nd Interim | 1st Interim | |
Ex-Div | 22-Feb-24 | 10-Aug-23 |
Paid | 25-Mar-24 | 11-Sep-23 |
Amount | 197.00¢ | 93.00¢ |
Time | Volume / Share Price |
10:14 | 61 @ 12,090.00p |
10:14 | 43 @ 12,090.00p |
10:14 | 20 @ 12,090.00p |
10:14 | 4 @ 12,090.00p |
10:14 | 61 @ 12,092.00p |
You are here: research